adesso (ADN1) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
8 Jul, 2026Executive summary
Achieved 14% organic sales growth in 2024, reaching approximately EUR 1.3 billion, outpacing market growth and supported by international expansion.
EBITDA rose 23% year-over-year to EUR 98.3 million (excluding one-off effects), with margin improving to 7.6% and a strong H2 margin of 10.6%.
Net income increased to EUR 10.2 million, with EPS at EUR 1.25, both significantly higher than the prior year.
Share buyback program completed, acquiring 1.9% of shares for EUR 10 million, supporting share price growth.
Dividend proposal increased to EUR 0.75 per share for 2024, reflecting optimism.
Financial highlights
Sales grew 14% year-over-year to EUR 1,297.0 million in 2024, driven almost entirely by organic growth.
EBITDA margin improved to 7.6% (excluding one-off effects), with operating cash flow up 44% to EUR 110.6 million.
Free cash flow per share improved to EUR 6.92, with total free cash flow at EUR 45.1 million, up 217% year-over-year.
Net working capital reduced by 8% to EUR 162.8 million; equity ratio decreased to 24.2%.
Return on equity averaged 12.4% over five years; 2024 ROE at 5.3%.
Outlook and guidance
2025 revenue guidance set at EUR 1.35–1.45 billion, representing 4–12% growth.
EBITDA forecasted at EUR 105–125 million, with margin expected to improve to above 8% due to higher utilisation and reduced investments.
Dividend proposal increased from EUR 0.17 to EUR 0.75 per share.
Anticipates slow start in public sector due to delayed budgets, but expects recovery in H2.
SAP and shoring initiatives in India expected to drive margin improvements.
Latest events from adesso
- Sales up 11% in Q1 2025; margin recovery and stronger H2 earnings expected.ADN1
Q1 2025 TU9 Jul 2026 - Sales and EBITDA grew 12% and 34% in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 20258 Jul 2026 - Sales up 16% to €631.1m, but negative EPS and EBITDA guidance cut amid margin pressure.ADN1
H1 20248 Jul 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 202611 May 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025